Hyphens Pharma International Limited

Equities

1J5

SG1EE4000006

Pharmaceuticals

Market Closed - Singapore S.E. 11:25:03 2024-04-18 pm EDT 5-day change 1st Jan Change
0.27 SGD -1.82% Intraday chart for Hyphens Pharma International Limited 0.00% -5.26%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Hyphens Pharma’s Attributable Profit Narrows in 2023 MT
Hyphens Pharma International Limited Proposes Final Tax Exempt (One-Tier) Dividend CI
Hyphens Pharma Buys Back Shares MT
CGS-CIMB Adjusts Hyphens Pharma’s Price Target to SG$0.35 From SG$0.32, Keeps at Add MT
Hyphens Pharma Obtains License to MC2's Psoriasis Cream MT
Hyphens Pharma International Limited Signs Exclusive Distribution Agreement with Cooper Pharma, S.A CI
Hyphens Pharma International Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Hyphens Pharma Strikes Distribution Deal With 7-Eleven Singapore MT
Hyphens Pharma Partners 7-Eleven to Offer Ocean Health Supplements in Singapore CI
Hyphens Pharma International Grants Nearly 6 Million Shares Under Performance Share Plan MT
CGS-CIMB Adjusts Hyphens Pharma’s Price Target to SG$0.32 From SG$0.34, Keeps at Add MT
Hyphens Pharma International Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Hyphens Pharma Unit Completes Purchase of First Tranche of Remaining Ardence Pharma Stake MT
Hyphens Pharma to Acquire Remaining 58% Stake in Ardence Pharma MT
Hyphens Pharma Unit to Distribute Daewoong Pharmaceutical's Nabota Botox in Malaysia MT
Hyphens Pharma International Limited Announces Special Interim Tax Exempt (One-Tier) Dividend for the Financial Year Ending 31 December 2023, Paid on 31 August 2023 CI
Hyphens Pharma International Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Hyphens Pharma Names CFO MT
Hyphens Pharma International Limited Appoints Zhang Yufan as Chief Financial Officer CI
Singapore Shares Return to Green; Hyphens Pharma Rises 5% on Deal to Develop Sedation Drug in Singapore MT
Hyphens Pharma to Develop, Commercialize Hana Pharm's Sedation Drug in Singapore MT
Singapore Stocks End Week in Red; Hyphens Pharma Shares Plummet 12% as Net Profit Dives 57% in Q1 MT
Hyphens Pharma's Net Profit Dives 57% in Q1; Shares Fall 14% MT
Hyphens Pharma International Limited Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Hyphens Pharma International Limited Approves to Declare Final Tax Exempt (One-Tier) Dividend for the Financial Year Ended 31 December 2022 CI
Chart Hyphens Pharma International Limited
More charts
Hyphens Pharma International Limited is a Singapore-based specialty pharmaceutical and consumer healthcare company. The Company's principal activities are those of an investment holding company and provision of management services. The Company's segments include Specialty pharma principals, Proprietary brands, and Medical hypermart and digital. The Specialty pharma principals segment is engaged in the business of marketing and selling a range of specialty pharmaceutical products with exclusivity in the relevant ASEAN countries. The Proprietary brands segment is engaged in the business of developing, marketing and selling its own proprietary range of dermatological products and health supplement products. The Medical hypermart and digital segment is a wholesaler of pharmaceuticals and medical supplies in Singapore, which the Company and its subsidiaries position themselves as a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.275 SGD
Average target price
0.35 SGD
Spread / Average Target
+27.27%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 1J5 Stock
  4. News Hyphens Pharma International Limited
  5. Hyphens Pharma International Logs Higher Profit in Q3 Despite Lower Revenue